Testing PRA-216 safety in COPD patients
Part of Lungs & breathing clinical trials.
This trial is testing a new drug called PRA-216 for people with COPD to see if it is safe and how it affects certain markers in the body. It may be an option if you have stable COPD and are on regular medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have had a COPD diagnosis for at least 1 year.
- You take COPD medications that have not changed in the last 2 months.
- You do not have another major lung disease besides COPD.
- You have not taken immunosuppressants for asthma in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
This study tests an investigational drug called PRA-216, first in healthy volunteers to check safety, then in people with mild-to-moderate asthma to see if it helps control symptoms. It's an early-stage trial to find out if the drug is safe and works.
This trial tests an injection called RC1416 for people with moderate-to-severe COPD who still have flare-ups despite using triple inhaler therapy. It may help reduce those flare-ups and improve breathing.
This trial tests a new medicine called 611 for people with moderate to severe COPD. It aims to see if adding 611 to your current treatments can help prevent flare-ups and improve symptoms.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
This study tests a new drug called WIN378 in people with moderate-to-severe COPD (chronic lung disease). It will check if the drug is safe and how the body processes it, which may help improve breathing and reduce flare-ups.
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.